Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Stoke Therapeutics is a biotechnology business based in the US. Stoke Therapeutics shares (STOK) are listed on the NASDAQ and all prices are listed in US Dollars. Stoke Therapeutics employs 117 staff and has a trailing 12-month revenue of around $12.4 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $8.17 |
|---|---|
| 52-week range | $6.88 - $26.00 |
| 50-day moving average | $9.21 |
| 200-day moving average | $12.08 |
| Wall St. target price | $31.64 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.60 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.17 from 2023-03-20
| 1 week (2023-03-15) | -10.71% |
|---|---|
| 1 month (2023-02-22) | -7.58% |
| 3 months (2022-12-22) | -3.20% |
| 6 months (2022-09-22) | -45.17% |
| 1 year (2022-03-22) | -67.23% |
|---|---|
| 2 years (2021-03-22) | -82.69% |
| 3 years (2020-03-20) | 22.21 |
| 5 years (2018-03-18) | N/A |
| Revenue TTM | $12.4 million |
|---|---|
| Gross profit TTM | $12.4 million |
| Return on assets TTM | -26.36% |
| Return on equity TTM | -50.2% |
| Profit margin | 0% |
| Book value | $4.69 |
| Market capitalisation | $404 million |
TTM: trailing 12 months
We're not expecting Stoke Therapeutics to pay a dividend over the next 12 months.
Stoke Therapeutics's shares were split on a 1:9 basis on 5 June 2019. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Stoke Therapeutics shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Stoke Therapeutics shares which in turn could have impacted Stoke Therapeutics's share price.
Over the last 12 months, Stoke Therapeutics's shares have ranged in value from as little as $6.88 up to $26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Stoke Therapeutics's is 0.4207. This would suggest that Stoke Therapeutics's shares are less volatile than average (for this exchange).
Stoke Therapeutics, Inc. , an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.